Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Drugs that inhibit RAF/MEK signaling, such as vemurafenib, elicit profound but often temporary anti‐tumor responses in patients with BRAF V 600E melanoma. Adaptive responses to RAF/MEK inhibition occur on a timescale of hours to days, involve homeostatic responses that reactivate MAP kinase signaling and compensatory mitogenic pathways, and attenuate the anti‐tumor effects of RAF/MEK inhibitors. We profile adaptive responses across a panel of melanoma cell lines using multiplex biochemical measurement, single‐cell assays, and statistical modeling and show that adaptation involves at least six signaling cascades that act to reduce drug potency (IC 50 ) and maximal effect (i.e., E max ≪ 1). Among these cascades, we identify a role for JNK/c‐Jun signaling in vemurafenib adaptation and show that RAF and JNK inhibitors synergize in cell killing. This arises because JNK inhibition prevents a subset of cells in a cycling population from becoming quiescent upon vemurafenib treatment, thereby reducing drug E max . Our findings demonstrate the breadth and diversity of adaptive responses to RAF/MEK inhibition and a means to identify which steps in a signaling cascade are most predictive of phenotypic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Data-driven modeling reveals signaling correlates of BRAF-mutant melanoma cellular response to RAF/MEK inhibition Overview of the systematic measurements using single-cell phenotypic and multiplex biochemical assays to profile signaling biochemistry and cell state in 10 BRAFV600E/D melanoma cell lines exposed to four RAF inhibitors and one MEK inhibitor at multiple doses and times. Multiplex single-cell immunofluorescence assays were used in the follow-up experiments on selected cell lines for treatments with vemurafenib, JNK-IN-8, and their combination. Dose–response curves representing 72-h viability measurements for six selected BRAFV600E melanoma cell lines after treatment with vemurafenib. Ranges of estimated IC50 and Emax for the selected lines are shown. Data are represented as mean ± SD. Pairwise distribution and correlation of estimated IC50 and Emax values for responses (72-h viability) of 8 cell lines to four RAF inhibitors and one MEK inhibitor. Each dot represents one drug/cell line combination. Sensitive cell lines are arbitrarily defined based on their IC50s (the most widely used metric for evaluation of drug response; log10[IC50] < −6.5). Cell line-specific model calibration for two selected cell lines C32 and WM115. Left: R2, Q2, and MSPE for C32 and WM115 models built with increasing numbers of PLSR components. Middle: Relative viability as measured experimentally (z-score-scaled) or as predicted by the three-component PLSR models using tenfold cross-validation. R2 reports model fit, and Q2 reports model prediction accuracy. Right: PLSR score plots for the first two components of C32 and WM115 models. Shown PLSR models were developed using RPPA data from Supplementary Dataset S3. PLSR loading plots for the first two components of C32 and WM115 models. Source data are available online for this figure.](https://figures.cochat.ai/paper-figures/b579f60ae84b4e3ca9fbe8346f715fc7/systematic-analysis-of-brafv600e-melanomas-reveals-a-role-for-jnk-cjun-pathway-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This is consistent with BRAFV600E melanoma studies that demonstrated a role for the JNK/c-Jun signaling pathway in vemurafenib adaptation and resistance to drug-induced apoptosis [55].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The BRAFV600E oncoprotein constitutively activates pro-mitogenic RAF/MEK/ERK signaling (Davies et al, 2002; Fecher et al, 2008), and therapy with RAF inhibitors such as vemurafenib (Zelboraf ; PLX4032) causes tumor regression in many patients (Bollag et al, 2010; Chapman et al, 2011; Flaherty et…”
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 2×
“For 25 BRAFV600E melanoma lines in the Cancer Cell Line Encyclopedia (Barretina et al, 2012), we also observed a statistically significant correlation between JUN expression levels and PLX4720 sensitivity Molecular Systems Biology 11: 797 | 2015 ª 2015 The Authors (Spearman’s q = 0.47, P = 0.02; see below; Supplementa…”
InfluentialImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 6×
“…potential biomarkers. pS6 has been proposed as a clinical biomarker for assessing the effectiveness of targeted therapy in BRAFV600E tumors (Corcoran et al, 2013), and our data add the insight that c-Jun up-regulation can also be estimated by measuring pS6 levels. pS6 levels are a…”
InfluentialPartial least-squares regression: a tutorial
Geladi, P., & Kowalski, B. R. (1986) · Analytica Chimica Acta · doi:10.1016/0003-2670(86)80028-9 · Cited by 6,992 · cited 2×
“We used partial least squares regression (PLSR) modeling (Geladi & Kowalski, 1986; Janes & Yaffe, 2006) to identify statistically significant covariation between molecular signals (input data; measured by RPPA) and corresponding cellular responses (output data; relative viability and apoptotic…”
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646 · cited 1×
“…protein on Ser807/811, a modification that promotes cell cycle progression and is present during the S/G2/M phases of the cell cycle, and the levels of nuclear Ki-67, a marker of proliferation that scores negative only in quiescent cells (Buchkovich et al, 1989; Scholzen & Gerdes, 2000).”
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103 · cited 1×
“However, the duration of response is variable and relapse to lethal drug-resistant disease is common (Flaherty et al, 2010).”
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · cited 1×
“…activates pro-mitogenic RAF/MEK/ERK signaling (Davies et al, 2002; Fecher et al, 2008), and therapy with RAF inhibitors such as vemurafenib (Zelboraf ; PLX4032) causes tumor regression in many patients (Bollag et al, 2010; Chapman et al, 2011; Flaherty et al, 2012; Sosman et al, 2012).”
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Seven of the tested cell lines have been genetically characterized through the Cancer Genome Project (Garnett et al, 2012) (Supplementary Dataset S1).”
Self-citationBendall, S. C., Simonds, E. F., Qiu, P., Amir, E.-A. D., Krutzik, P. O., Finck, R., Bruggner, R. V., Melamed, R., Trejo, A., Ornatsky, O. I., et al. (2011) · Science · doi:10.1126/science.1198704 · Cited by 2,279 · cited 1×
“In principle, it may be advantageous to use high-multiplicity single-cell imaging for primary data collection (Bendall et al, 2011; Gerdes et al, 2013).”
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192 · cited 2×
“Many mutations involved in acquired resistance have been identified, including NRASQ61K, MEK1F129L, MEK2Q60P, or AKT1Q79K (Nazarian et al, 2010; Wang et al, 2011; Shi et al, 2014a; Wagle et al, 2014), and aberrant splicing of BRAFV600E (Poulikakos et al, 2011).”
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“…activates pro-mitogenic RAF/MEK/ERK signaling (Davies et al, 2002; Fecher et al, 2008), and therapy with RAF inhibitors such as vemurafenib (Zelboraf ; PLX4032) causes tumor regression in many patients (Bollag et al, 2010; Chapman et al, 2011; Flaherty et al, 2012; Sosman et al, 2012).”
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831 · cited 1×
“…activates pro-mitogenic RAF/MEK/ERK signaling (Davies et al, 2002; Fecher et al, 2008), and therapy with RAF inhibitors such as vemurafenib (Zelboraf ; PLX4032) causes tumor regression in many patients (Bollag et al, 2010; Chapman et al, 2011; Flaherty et al, 2012; Sosman et al, 2012).”
Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data
Sachs, K., Perez, O., Pe'er, D., Lauffenburger, D. A., & Nolan, G. P. (2005) · Science · doi:10.1126/science.1105809 · Cited by 1,708 · cited 1×
“Different network inference methods such as logical or Bayesian network modeling in combination with literature-based prior knowledge may be helpful next steps (Sachs et al, 2002, 2005; Morris et al, 2011; Saez-Rodriguez et al, 2011).”
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460 · cited 1×
“Resistance is also associated with elevated IGF1 receptor/PI3K signaling (Villanueva et al, 2010), COT overexpression (Johannessen et al, 2010), and PDGFRb up-regulation (Nazarian et al, 2010).”
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259 · cited 1×
“Resistance is also associated with elevated IGF1 receptor/PI3K signaling (Villanueva et al, 2010), COT overexpression (Johannessen et al, 2010), and PDGFRb up-regulation (Nazarian et al, 2010).”
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198 · cited 1×
“Adaptive responses are thought to reflect feedback mechanisms involved in signaling homeostasis (O’Reilly et al, 2006; Carver et al, 2011; Chandarlapaty et al, 2011).”
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077 · cited 1×
“…et al, 2012; Corcoran et al, 2013), a multiprotein complex controlled by signaling cascades such as MAPK, PI3K/AKT, and LKB1/AMPK (Roux et al, 2004; Shaw et al, 2004; Magnuson et al, 2012) involved in adaptation to vemurafenib (a point we return to below). pS6 levels have previously been proposed…”
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015 · cited 2×
“To monitor the effect of vemurafenib at the level of signaling, we measured S6 phosphorylation (Ser235/236). pS6 is a marker of TORC1 activity (Magnuson et al, 2012; Corcoran et al, 2013), a multiprotein complex controlled by signaling cascades such as MAPK, PI3K/AKT, and LKB1/AMPK (Roux et al,…”
The retinoblastoma protein is phosphorylated during specific phases of the cell cycle
Buchkovich, K., Duffy, L. A., & Harlow, E. (1989) · Cell · doi:10.1016/0092-8674(89)90508-4 · Cited by 995 · cited 1×
“…protein on Ser807/811, a modification that promotes cell cycle progression and is present during the S/G2/M phases of the cell cycle, and the levels of nuclear Ki-67, a marker of proliferation that scores negative only in quiescent cells (Buchkovich et al, 1989; Scholzen & Gerdes, 2000).”
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982 · cited 7×
“…et al, 2012; Lito et al, 2012; Muranen et al, 2012; Shi et al, 2014a; Solit & Rosen, 2014), and it is thought that the resulting “partial” response to RAF inhibition increases the probability that genetic changes leading to acquired resistance will arise (Lito et al, 2013; Shi et al, 2014a,b).”
InfluentialAKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · cited 1×
“Adaptive responses are thought to reflect feedback mechanisms involved in signaling homeostasis (O’Reilly et al, 2006; Carver et al, 2011; Chandarlapaty et al, 2011).”
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888 · cited 2×
“Insensitivity to RAF inhibition in BRAFV600E melanomas frequently arises from adaptive responses that reactivate ERK (Lito et al, 2012) or up-regulate other pro-growth pathways such as the PI3K/AKT cascade (Shi et al, 2014a; Sun et al, 2014).”
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769 · cited 2×
“According to this model, the excess above the predicted Bliss independence represents the synergistic effect of the combination treatment (Keith et al, 2005).”
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750 · cited 2×
“…(Magnuson et al, 2012; Corcoran et al, 2013), a multiprotein complex controlled by signaling cascades such as MAPK, PI3K/AKT, and LKB1/AMPK (Roux et al, 2004; Shaw et al, 2004; Magnuson et al, 2012) involved in adaptation to vemurafenib (a point we return to below). pS6 levels have…”
Role of JNK activation in apoptosis: A double-edged sword
LIU, J., & LIN, A. (2005) · Cell Research · doi:10.1038/sj.cr.7290262 · Cited by 738 · cited 2×
“The JNK/c-Jun pathway as an adaptive mechanism inhibiting drug-induced apoptosis The function of JNK in cancer is complex and context-dependent and has been linked to differential functions of the three isoforms (JNK1–JNK3) (Liu & Lin, 2005), complicating the development of JNK inhibitors as anti-cancer drugs.”
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732 · cited 1×
“Changes consistent with adaptation have been observed not only in cell lines but also in clinical biopsies (Chandarlapaty, 2012; Duncan et al, 2012; Lito et al, 2012; Muranen et al, 2012; Shi et al, 2014a; Solit & Rosen, 2014), and it is thought that the resulting “partial” response to RAF…”
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue
Gerdes, M. J., Sevinsky, C. J., Sood, A., Adak, S., Bello, M. O., Bordwell, A., Can, A., Corwin, A., Dinn, S., Filkins, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300136110 · Cited by 724 · cited 1×
“In principle, it may be advantageous to use high-multiplicity single-cell imaging for primary data collection (Bendall et al, 2011; Gerdes et al, 2013).”
c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms
Wisdom, R. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.188 · Cited by 685 · cited 2×
“…the inhibition of proliferation from induction of apoptosis. c-Jun has well-recognized roles in regulating both proliferation and apoptosis (Wisdom et al, 1999), but in melanoma it is thought to function downstream of ERK by promoting transcription of cyclin D1, a positive regulator of the…”
Shi, H., Moriceau, G., Kong, X., Lee, M.-K., Lee, H., Koya, R. C., Ng, C., Chodon, T., Scolyer, R. A., Dahlman, K. B., et al. (2012) · Nature Communications · doi:10.1038/ncomms1727 · Cited by 640 · cited 1×
“Resistance usually involves the activation of progrowth/survival mechanisms that increase BRAFV600E activity (Shi et al, 2012) or bypass the need for it altogether.”
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585 · cited 2×
“…et al, 2012; Lito et al, 2012; Muranen et al, 2012; Shi et al, 2014a; Solit & Rosen, 2014), and it is thought that the resulting “partial” response to RAF inhibition increases the probability that genetic changes leading to acquired resistance will arise (Lito et al, 2013; Shi et al, 2014a,b).”
Lito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, W. L., Callahan, M. K., Merghoub, T., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.009 · Cited by 562 · cited 2×
“Insensitivity to RAF inhibition in BRAFV600E melanomas frequently arises from adaptive responses that reactivate ERK (Lito et al, 2012) or up-regulate other pro-growth pathways such as the PI3K/AKT cascade (Shi et al, 2014a; Sun et al, 2014).”
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · cited 1×
“Many mutations involved in acquired resistance have been identified, including NRASQ61K, MEK1F129L, MEK2Q60P, or AKT1Q79K (Nazarian et al, 2010; Wang et al, 2011; Shi et al, 2014a; Wagle et al, 2014), and aberrant splicing of BRAFV600E (Poulikakos et al, 2011).”
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Muranen, T., Selfors, L. M., Worster, D. T., Iwanicki, M. P., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 384
Data-driven modelling of signal-transduction networks
Janes, K. A., & Yaffe, M. B. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2041 · Cited by 356 · cited 2×
“We used partial least squares regression (PLSR) modeling (Geladi & Kowalski, 1986; Janes & Yaffe, 2006) to identify statistically significant covariation between molecular signals (input data; measured by RPPA) and corresponding cellular responses (output data; relative viability and apoptotic…”
Discovery of Potent and Selective Covalent Inhibitors of JNK
Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 349 · cited 2×
“The addition of an irreversible JNK inhibitor (Zhang et al, 2012) synergized with vemurafenib in cell killing, primarily by increasing Emax.”
Self-citationMetrics other than potency reveal systematic variation in responses to cancer drugs
Fallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Gray, J. W., & Sorger, P. K. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1337 · Cited by 314 · cited 2×
“Variation in Emax and in the slope of the dose– response curve can play a significant role in limiting the efficacy of anti-cancer drugs (Fallahi-Sichani et al, 2013).”
Self-citationRewired ERK-JNK Signaling Pathways in Melanoma
Lopez-Bergami, P., Huang, C., Goydos, J. S., Yip, D., Bar-Eli, M., Herlyn, M., Smalley, K. S. M., Mahale, A., Eroshkin, A., Aaronson, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.009 · Cited by 286 · cited 2×
“…of apoptosis. c-Jun has well-recognized roles in regulating both proliferation and apoptosis (Wisdom et al, 1999), but in melanoma it is thought to function downstream of ERK by promoting transcription of cyclin D1, a positive regulator of the G1-S cell cycle transition (Lopez-Bergami et al, 2007).”
Exponentially weighted moving principal components analysis and projections to latent structures
Wold, S. (1994) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/0169-7439(93)e0075-f · Cited by 253 · cited 3×
“VIP scores report the sum (over all model dimensions) of each variable x (an RPPA assay at a specific time point), weighted by the change in response (cell viability) explained by the same variable x (see Materials and Methods for mathematical details) (Wold, 1994; Janes et al, 2008).”
Fecher, L. A., Amaravadi, R. K., & Flaherty, K. T. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f5271c · Cited by 249 · cited 1×
“The BRAFV600E oncoprotein constitutively activates pro-mitogenic RAF/MEK/ERK signaling (Davies et al, 2002; Fecher et al, 2008), and therapy with RAF inhibitors such as vemurafenib (Zelboraf ; PLX4032) causes tumor regression in many patients (Bollag et al, 2010; Chapman et al, 2011; Flaherty et…”
Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
Chandarlapaty, S. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0018 · Cited by 234 · cited 2×
“Changes consistent with adaptation have been observed not only in cell lines but also in clinical biopsies (Chandarlapaty, 2012; Duncan et al, 2012; Lito et al, 2012; Muranen et al, 2012; Shi et al, 2014a; Solit & Rosen, 2014), and it is thought that the resulting “partial” response to RAF…”
Phenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanoma
Yuan, P., Ito, K., Perez-Lorenzo, R., Del Guzzo, C., Lee, J. H., Shen, C.-H., Bosenberg, M. W., McMahon, M., Cantley, L. C., & Zheng, B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317577110 · Cited by 218 · cited 1×
“…suppression of S6 phosphorylation (pS6(Ser235/236)) has been reported to be a good predictor of weak responsiveness to RAF inhibition in cell lines and patient-derived biopsies (Corcoran et al, 2013; Yuan et al, 2013) reflecting the role of S6 in integrating MAPK and adaptive signaling.”
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Shi, H., Hong, A., Kong, X., Koya, R. C., Song, C., Moriceau, G., Hugo, W., Yu, C. C., Ng, C., Chodon, T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0279 · Cited by 173 · cited 7×
“…et al, 2012; Lito et al, 2012; Muranen et al, 2012; Shi et al, 2014a; Solit & Rosen, 2014), and it is thought that the resulting “partial” response to RAF inhibition increases the probability that genetic changes leading to acquired resistance will arise (Lito et al, 2013; Shi et al, 2014a,b).”
Influentialc-Jun promotes cellular survival by suppression of PTEN
Hettinger, K., Vikhanskaya, F., Poh, M. K., Lee, M. K., de Belle, I., Zhang, J.-T., Reddy, S. A. G., & Sabapathy, K. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401946 · Cited by 159 · cited 1×
“…might also reflect a role for c-Jun in controlling expression of proteins in the TORC1 pathway such as phosphoinositide-dependent kinase 1 (PDK1; an activator of AGC kinase families such as AKT and S6 kinases), PTEN, and EGFR (Johnson et al, 2000; Hettinger et al, 2007; LopezBergami et al, 2010).”
A Compendium of Signals and Responses Triggered by Prodeath and Prosurvival Cytokines
Gaudet, S., Janes, K. A., Albeck, J. G., Pace, E. A., Lauffenburger, D. A., & Sorger, P. K. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500158-mcp200 · Cited by 155 · cited 1×
“Model fitness was calculated using R2, Q2, and mean squared prediction error (MSPE) which were calculated as previously described (Gaudet et al, 2005).”
Self-citationSaez-Rodriguez, J., Alexopoulos, L. G., Zhang, M., Morris, M. K., Lauffenburger, D. A., & Sorger, P. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4453 · Cited by 147
Self-citationTORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140 · cited 6×
“…potential biomarkers. pS6 has been proposed as a clinical biomarker for assessing the effectiveness of targeted therapy in BRAFV600E tumors (Corcoran et al, 2013), and our data add the insight that c-Jun up-regulation can also be estimated by measuring pS6 levels. pS6 levels are a…”
InfluentialRb binds c‐Jun and activates transcription
Nead, M. A., Baglia, L. A., Antinore, M. J., Ludlow, J. W., & McCance, D. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.8.2342 · Cited by 125 · cited 1×
“…c-Jun activity can be elicited by growth factors, inflammatory cytokines, cAMP-dependent pathways, cellular stress, and cell cycle regulators such as Rb and cyclin-dependent kinases (de Groot & Sassone-Corsi, 1992; Nead et al, 1998; Wisdom et al, 1999; Vanden Bush & Bishop, 2011; Sun et al, 2014).”
Morris, M. K., Saez-Rodriguez, J., Clarke, D. C., Sorger, P. K., & Lauffenburger, D. A. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001099 · Cited by 124 · cited 1×
“Different network inference methods such as logical or Bayesian network modeling in combination with literature-based prior knowledge may be helpful next steps (Sachs et al, 2002, 2005; Morris et al, 2011; Saez-Rodriguez et al, 2011).”
Self-citationBayesian Network Approach to Cell Signaling Pathway Modeling
Sachs, K., Gifford, D., Jaakkola, T., Sorger, P., & Lauffenburger, D. A. (2002) · Science's STKE · doi:10.1126/stke.2002.148.pe38 · Cited by 120 · cited 1×
“Different network inference methods such as logical or Bayesian network modeling in combination with literature-based prior knowledge may be helpful next steps (Sachs et al, 2002, 2005; Morris et al, 2011; Saez-Rodriguez et al, 2011).”
Self-citationTreatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
Jang, S., & Atkins, M. B. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.197 · Cited by 103
Cytokine-Induced Signaling Networks Prioritize Dynamic Range over Signal Strength
Janes, K. A., Reinhardt, H. C., & Yaffe, M. B. (2008) · Cell · doi:10.1016/j.cell.2008.08.034 · Cited by 99 · cited 2×
“VIP scores report the sum (over all model dimensions) of each variable x (an RPPA assay at a specific time point), weighted by the change in response (cell viability) explained by the same variable x (see Materials and Methods for mathematical details) (Wold, 1994; Janes et al, 2008).”
Flusberg, D. A., Roux, J., Spencer, S. L., & Sorger, P. K. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-10-0737 · Cited by 96 · cited 1×
“This is particularly true in the case of apoptosis, which is an all-or-none change in cell fate (Flusberg et al, 2013).”
Self-citationBRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
Vin, H., Ojeda, S. S., Ching, G., Leung, M. L., Chitsazzadeh, V., Dwyer, D. W., Adelmann, C. H., Restrepo, M., Richards, K. N., Stewart, L. R., et al. (2013) · eLife · doi:10.7554/elife.00969 · Cited by 84 · cited 2×
“Phospho-p38(Thr180/Tyr182) levels also fell within 1 h of exposure to vemurafenib, PLX4720, or AZ628; KINOMEscan binding data for these drugs (Vin et al, 2013) suggest that they have off-target activity on regulators of p38 such as ZAK kinases.”
Wang, H., Daouti, S., Li, W.-H., Wen, Y., Rizzo, C., Higgins, B., Packman, K., Rosen, N., Boylan, J. F., Heimbrook, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4351 · Cited by 76 · cited 1×
“Many mutations involved in acquired resistance have been identified, including NRASQ61K, MEK1F129L, MEK2Q60P, or AKT1Q79K (Nazarian et al, 2010; Wang et al, 2011; Shi et al, 2014a; Wagle et al, 2014), and aberrant splicing of BRAFV600E (Poulikakos et al, 2011).”
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays
Gujral, T. S., Karp, R. L., Finski, A., Chan, M. M., Schwartz, P. E., MacBeath, G., & Sorger, P. K. (2012) · Oncogene · doi:10.1038/onc.2012.378 · Cited by 75 · cited 1×
“Analysis of patient-derived cell cultures is another obvious extension, and we have previously shown that RPPA can be used to perform multiplex analysis of signaling in tumor lysates (Gujral et al, 2013).”
Self-citationActivator Protein-1 Mediates Induced but not Basal Epidermal Growth Factor Receptor Gene Expression
Johnson, A. C., Murphy, B. A., Matelis, C. M., Rubinstein, Y., Piebenga, E. C., Akers, L. M., Neta, G., Vinson, C., & Birrer, M. (2000) · Molecular Medicine · doi:10.1007/bf03401931 · Cited by 72
JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis
Alexaki, V., Javelaud, D., & Mauviel, A. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00466.x · Cited by 62 · cited 1×
“It has also been reported that JNK activity promotes growth and survival of melanoma cells under unstressed conditions (Lopez-Bergami et al, 2007; Alexaki et al, 2008; Gurzov et al, 2008).”
Activation of Jun/AP-1 by protein kinase A.
de Groot, R. P., & Sassone‐Corsi, P. (1992) · PubMed · Cited by 56
Targeting c-Jun and JunB proteins as potential anticancer cell therapy
Gurzov, E. N., Bakiri, L., Alfaro, J. M., Wagner, E. F., & Izquierdo, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210690 · Cited by 53 · cited 1×
“It has also been reported that JNK activity promotes growth and survival of melanoma cells under unstressed conditions (Lopez-Bergami et al, 2007; Alexaki et al, 2008; Gurzov et al, 2008).”
Towards a Unified Model of RAF Inhibitor Resistance
Solit, D. B., & Rosen, N. X. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0961 · Cited by 50 · cited 1×
“…only in cell lines but also in clinical biopsies (Chandarlapaty, 2012; Duncan et al, 2012; Lito et al, 2012; Muranen et al, 2012; Shi et al, 2014a; Solit & Rosen, 2014), and it is thought that the resulting “partial” response to RAF inhibition increases the probability that genetic changes…”
Lysate Microarrays Enable High-throughput, Quantitative Investigations of Cellular Signaling*
Sevecka, M., Wolf-Yadlin, A., & MacBeath, G. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.005363 · Cited by 42 · cited 2×
“Signaling proteins were assayed at seven drug doses between 3.2 nM and 3.2 lM and five time points between 1 and 48 h by RPPA (Sevecka et al, 2011) using antibodies with good coverage of cell growth, apoptosis, stress response, and energy homeostasis pathways as well as 4 cell state markers (see…”
Influentialc-Jun Regulates Phosphoinositide-dependent Kinase 1 Transcription
Lopez-Bergami, P., Kim, H., Dewing, A., Goydos, J., Aaronson, S., & Ronai, Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075630 · Cited by 39
CDK-Mediated Regulation of Cell Functions via c-Jun Phosphorylation and AP-1 Activation
Bush, T. J. V., & Bishop, G. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019468 · Cited by 34 · cited 2×
“…c-Jun activity can be elicited by growth factors, inflammatory cytokines, cAMP-dependent pathways, cellular stress, and cell cycle regulators such as Rb and cyclin-dependent kinases (de Groot & Sassone-Corsi, 1992; Nead et al, 1998; Wisdom et al, 1999; Vanden Bush & Bishop, 2011; Sun et al, 2014).”
Smalley, I., Fang, B., Munko, A., Gibney, G. T., Koomen, J. M., & Smalley, K. S. M. (2014) · PROTEOMICS · doi:10.1002/pmic.201400200 · Cited by 16 · cited 1×
“Future improvements to the approach include the use of alternative multiplexing methods including mass spectrometry to perform a deeper analysis of signaling under selected conditions (Fedorenko et al, 2015).”
Abstract 5400: Antiangiogenic gene therapy with VB111 is active in glioblastoma xenografts
Brenner, A. J., Rogge, J., Cohen, Y. C., Breitbart, E., & Bangio, L. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-5400 · Cited by 15
Tang, Y., Xie, T., Florian, S., Moerke, N. J., Shamu, C. E., Benes, C. H., & Mitchison, T. J. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113493804 · Cited by 8 · cited 2×
“Cell viability and apoptosis assays To score viability and apoptosis, we used a dye-based imaging assay; the cell-permeable DNA dye, Hoechst 33342, was used to mark nuclei and DEVD-NucView488 caspase-3 substrate was used to mark apoptosis (Tang et al, 2013).”
Self-citation
Cited by
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method
Lin, J.-R., Fallahi-Sichani, M., & Sorger, P. K. (2015) · Nature Communications · doi:10.1038/ncomms9390 · Cited by 562
“…the application of CycIF to drug response at a single-cell level and show that multiplex single-cell measurement reveals new aspects of drug sensitivity and resistance 22,23 ; further refinement of the method will be reported at our web site at http://lincs.hms.harvard.edu/lin-NatCommun-2015.”
Self-citationThe JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer
Hammouda, M., Ford, A., Liu, Y., & Zhang, J. (2020) · Cells · doi:10.3390/cells9040857 · Cited by 284
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 235
“To score viability and apoptosis, we used a dyebased imaging assay: The cell-permeable DNA dye Hoechst 33342 was used to mark nuclei, and DEVD-NucView488 caspase-3 substrate was used to mark apoptosis, as previously described in detail (Fallahi-Sichani et al, 2015).”
InfluentialSelf-citationMiller, M. A., Oudin, M. J., Sullivan, R. J., Wang, S. J., Meyer, A. S., Im, H., Frederick, D. T., Tadros, J., Griffith, L. G., Lee, H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0933 · Cited by 166
Metadata
- Authors
- Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Sorger, Peter K
- Venue
- Molecular Systems Biology
- Published
- 2015-03-01
- Volume
- 11
- Issue
- 3
- Pages
- 797-797
- ISSN
- 1744-4292 (ISSN-L)
- PMC
- PMC4380931
- OpenAlex
- W2110682642
- Cited by
- 99
- References
- 68
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 14 · 2019: 12 · 2018: 12 · 2017: 11 · 2016: 8 · 2015: 7
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 25 d)
- Locations
- Molecular Systems Biology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- NIH LINCS Program (U54HG006097, U54HL127365, CA139980, CA130876)
- Merck Fellow of the Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BRAF V600E melanoma, vemurafenib, adaptive drug resistance, JNK/c-Jun signaling, MAPK signaling, drug synergy, cell cycle quiescence, melanoma cell lines, Emax, IC50, compensatory signaling pathways
- MeSH terms
- Vemurafenib, Cell Survival, Drug Synergism, Humans, Indoles, Melanoma, Mutation, Sulfonamides, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.